Business Description
Bioventus Inc
NAICS : 339112
SIC : 3845
ISIN : US09075A1088
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 2.58 | |||||
Debt-to-EBITDA | 12.02 | |||||
Interest Coverage | 0.44 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.96 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.4 | |||||
3-Year FCF Growth Rate | -54.6 | |||||
3-Year Book Growth Rate | -10.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.05 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 71.09 | |||||
9-Day RSI | 58.87 | |||||
14-Day RSI | 54.68 | |||||
6-1 Month Momentum % | 95.45 | |||||
12-1 Month Momentum % | 229.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.41 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 184.72 | |||||
Days Sales Outstanding | 81.6 | |||||
Days Payable | 40.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.8 | |||||
Shareholder Yield % | 2.65 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 67 | |||||
Operating Margin % | 3.17 | |||||
Net Margin % | -7.11 | |||||
FCF Margin % | 5.23 | |||||
ROE % | -24.01 | |||||
ROA % | -4.96 | |||||
ROIC % | 2.49 | |||||
ROC (Joel Greenblatt) % | -13.26 | |||||
ROCE % | -2.92 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 18.72 | |||||
PE Ratio without NRI | 29.05 | |||||
PS Ratio | 1.42 | |||||
PB Ratio | 5.38 | |||||
Price-to-Free-Cash-Flow | 27.19 | |||||
Price-to-Operating-Cash-Flow | 26.49 | |||||
EV-to-EBIT | -64.67 | |||||
EV-to-EBITDA | 35.83 | |||||
EV-to-Revenue | 2.06 | |||||
EV-to-Forward-Revenue | 1.88 | |||||
EV-to-FCF | 39.38 | |||||
Price-to-Projected-FCF | 4.22 | |||||
Earnings Yield (Greenblatt) % | -1.55 | |||||
FCF Yield % | 3.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BVS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Bioventus Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 555.061 | ||
EPS (TTM) ($) | -0.6 | ||
Beta | 1.01 | ||
Volatility % | 93.94 | ||
14-Day RSI | 54.68 | ||
14-Day ATR ($) | 0.72146 | ||
20-Day SMA ($) | 11.837 | ||
12-1 Month Momentum % | 229.46 | ||
52-Week Range ($) | 3.7987 - 14.38 | ||
Shares Outstanding (Mil) | 65.37 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bioventus Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bioventus Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Bioventus Inc Frequently Asked Questions
What is Bioventus Inc(BVS)'s stock price today?
When is next earnings date of Bioventus Inc(BVS)?
Does Bioventus Inc(BVS) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |